Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder
Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh
Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh
View: Text | PDF
Research Article Metabolism Neuroscience

Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder

  • Text
  • PDF
Abstract

Accumulation of lysosomal storage material and late-stage neurodegeneration are hallmarks of lysosomal storage disorders (LSDs) affecting the brain. Yet, for most LSDs, including CLN3 disease, the most common form of childhood dementia, it is unclear what mechanisms drive neurologic symptoms. Do deficits arise from loss of function of the mutated protein or toxicity from storage accumulation? Here, using in vitro voltage-sensitive dye imaging and in vivo electrophysiology, we find progressive hippocampal dysfunction occurs before notable lysosomal storage and neuronal loss in 2 CLN3 disease mouse models. Pharmacologic reversal of lysosomal storage deposition in young mice does not rescue this circuit dysfunction. Additionally, we find that CLN3 disease mice lose an electrophysiologic marker of new memory encoding — hippocampal sharp-wave ripples. This discovery, which is also seen in Alzheimer’s disease, suggests the possibility of a shared electrophysiologic signature of dementia. Overall, our data describe new insights into previously unknown network-level changes occurring in LSDs affecting the central nervous system and highlight the need for new therapeutic interventions targeting early circuit defects.

Authors

Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh

×

Figure 2

Activation of the CA3 and CA1 after perforant path stimulation are significantly decreased in CLN3–/– mice by 6 and 18 months of age, respectively.

Options: View larger image (or click on image) Download as PowerPoint
Activation of the CA3 and CA1 after perforant path stimulation are signi...
(A and B) Raster plots reveal that PP stimulation results in moderate excitation of both WT and CLN3–/– stratum radiatum of the hilus, CA3, and CA1 at 2 months of age. (C) Permutation sampling analysis at 2 months demonstrates minimal differences in excitability between WT and CLN3–/–. Pixels with P > 0.05 are masked in gray. For regions of significance with P < 0.05, the difference in fluorescence change (ΔF/FWT – ΔF/FCLN3KO) is shown. Cooler colors indicate relative hypoexcitability of the CLN3–/– CA proper. (D–F) At 6–7 months and (G–I) 18–21 months of age, there is progressive hypoexcitability throughout the CA proper. (J) Quantification of total fluorescence change in the hilus and CA3 regions supports hypoexcitability in CLN3–/– mice at 6 and 18 months. (K) The CA1 region demonstrates a significant decrease in excitability by 18 months. (J and K, 2-way ANOVA, followed by Tukey’s multiple-comparisons test). For all panels: *P < 0.05. Group sizes (n = slices, N = mice): 2-month WT n = 24, N = 6; 2-month CLN3–/– n = 26, N = 5; 6- to 7-month WT n = 23, N = 5; 6- to 7-month CLN3–/– n = 30, N = 8; 18- to 21-month WT n = 25, N = 7; 18- to 21-month CLN3 n = 26, N = 7. For all graphs mean ± SEM shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts